Protein corona variation in nanoparticles revisited: A dynamic grouping strategy.

Bio-nano interface investigation models are mainly based on the type of proteins present on corona, bio-nano interaction responses and the evaluation of final outcomes. Due to the extensive diversity in correlative models for investigation of nanoparticles biological responses, a comprehensive model considering different aspects of bio-nano interface from nanoparticles properties to protein corona fingerprints appeared to be essential and cannot be ignored. In order to minimize divergence in studies in the era of bio-nano interface and protein corona with following therapeutic implications, a useful investigation model on the basis of RADAR concept is suggested. The contents of RADAR concept consist of five modules: 1- Reshape of our strategy for synthesis of nanoparticles (NPs), 2- Application of NPs selected based on human fluid, 3- Delivery strategy of NPs selected based on target tissue, 4- Analysis of proteins present on corona using correct procedures and 5- Risk assessment and risk reduction upon the collection and analysis of results to increase drug delivery efficiency and drug efficacy. RADAR grouping strategy for revisiting protein corona phenomenon as a key of success will be discussed with respect to the current state of knowledge.

[1]  S. Cole,et al.  Applications of nanoparticle drug delivery systems for the reversal of multidrug resistance in cancer. , 2016, Oncology letters.

[2]  Davoud Ahmadvand,et al.  Material properties in complement activation. , 2011, Advanced drug delivery reviews.

[3]  M. Irizarry Biomarkers of Alzheimer disease in plasma , 2004, NeuroRX.

[4]  Morteza Mahmoudi,et al.  Personalized protein corona on nanoparticles and its clinical implications. , 2017, Biomaterials science.

[5]  J. Loo,et al.  Cellular uptake of Poly‐(D,L‐lactide‐co‐glycolide) (PLGA) nanoparticles synthesized through solvent emulsion evaporation and nanoprecipitation method , 2011, Biotechnology journal.

[6]  M. Papi,et al.  A protein corona-enabled blood test for early cancer detection. , 2017, Nanoscale.

[7]  Morteza Mahmoudi,et al.  A new approach for the in vitro identification of the cytotoxicity of superparamagnetic iron oxide nanoparticles. , 2010, Colloids and surfaces. B, Biointerfaces.

[8]  Warren C W Chan,et al.  Strategies for the intracellular delivery of nanoparticles. , 2011, Chemical Society reviews.

[9]  Manuela Semmler-Behnke,et al.  Size and surface charge of gold nanoparticles determine absorption across intestinal barriers and accumulation in secondary target organs after oral administration , 2011, Nanotoxicology.

[10]  Raehyun Kim,et al.  The importance of selecting a proper biological milieu for protein corona analysis in vitro: Human plasma versus human serum. , 2016, The international journal of biochemistry & cell biology.

[11]  K. Higaki,et al.  Prolongation of residence time of liposome by surface-modification with mixture of hydrophilic polymers. , 2008, International journal of pharmaceutics.

[12]  Heidi Ledford Bankruptcy filing worries developers of nanoparticle cancer drugs , 2016, Nature.

[13]  K. Langer,et al.  Comparative examination of adsorption of serum proteins on HSA- and PLGA-based nanoparticles using SDS-PAGE and LC-MS. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[14]  D. Choi,et al.  Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer’s disease , 2018, Drug delivery.

[15]  M. Mahmoudi,et al.  Monoclonal antibody conjugated magnetic nanoparticles could target MUC-1-positive cells in vitro but not in vivo. , 2015, Contrast media & molecular imaging.

[16]  Vladimir P Torchilin,et al.  Passive and active drug targeting: drug delivery to tumors as an example. , 2010, Handbook of experimental pharmacology.

[17]  J. Gubbins,et al.  Formation of protein corona in vivo affects drug release from temperature‐sensitive liposomes , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[18]  Christine Jérôme,et al.  Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[19]  W. Saltzman,et al.  The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. , 2009, Biomaterials.

[20]  R. Müller,et al.  Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: Comparison of plasma protein adsorption patterns , 2005, Journal of drug targeting.

[21]  Sara Linse,et al.  Modeling the Time Evolution of the Nanoparticle-Protein Corona in a Body Fluid , 2010, PloS one.

[22]  Morteza Mahmoudi,et al.  Personalized protein coronas: a "key" factor at the nanobiointerface. , 2014, Biomaterials science.

[23]  C. V. Vander Kooi,et al.  Structural Mechanism of Laforin Function in Glycogen Dephosphorylation and Lafora Disease , 2015, Molecular cell.

[24]  Giulio Caracciolo,et al.  Time evolution of nanoparticle-protein corona in human plasma: relevance for targeted drug delivery. , 2013, Langmuir : the ACS journal of surfaces and colloids.

[25]  B. Nilsson,et al.  Conformational epitopes of C3 reflecting its mode of binding to an artificial polymer surface. , 1993, Molecular immunology.

[26]  G. Caracciolo,et al.  Exploitation of nanoparticle-protein corona for emerging therapeutic and diagnostic applications. , 2016, Journal of materials chemistry. B.

[27]  D. Simberg,et al.  Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems , 2011, Expert opinion on drug delivery.

[28]  S. Radford,et al.  Nucleation of protein fibrillation by nanoparticles , 2007, Proceedings of the National Academy of Sciences.

[29]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[30]  Albert Duschl,et al.  Interaction of nanoparticles with proteins: relation to bio-reactivity of the nanoparticle , 2013, Journal of Nanobiotechnology.

[31]  Bernard Cabane,et al.  Protein adsorption and complement activation for di-block copolymer nanoparticles. , 2011, Biomaterials.

[32]  J. Kreuter,et al.  Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[33]  T. Faunce Integrated Research into the Nanoparticle-Protein Corona: A New Focus for Safe, Sustainable and Equitable Development of Nanomedicines , 2008, Nanomedicine.

[34]  K. Jain The Role of Nanobiotechnology in the Development of Personalized Medicine , 2010, Medical Principles and Practice.

[35]  G Ulrich Nienhaus,et al.  Studying the protein corona on nanoparticles by FCS. , 2013, Methods in enzymology.

[36]  Kenneth A Dawson,et al.  Nanoparticle adhesion to the cell membrane and its effect on nanoparticle uptake efficiency. , 2013, Journal of the American Chemical Society.

[37]  Ke Xu,et al.  Effect of Cell Sex on Uptake of Nanoparticles: The Overlooked Factor at the Nanobio Interface. , 2018, ACS nano.

[38]  L. J. Lee,et al.  Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7alpha-APTADD to breast cancer cells. , 2010, International journal of pharmaceutics.

[39]  G. Hill,et al.  Effects of an anabolic steroid on plasma amino acids, proteins, and body composition in patients receiving intravenous hyperalimentation. , 1983, JPEN - Journal of Parenteral and Enteral Nutrition.

[40]  S. Vyas,et al.  Ligand-receptor-mediated drug delivery: an emerging paradigm in cellular drug targeting. , 2001, Critical reviews in therapeutic drug carrier systems.

[41]  Vincent M Rotello,et al.  Acylsulfonamide-Functionalized Zwitterionic Gold Nanoparticles for Enhanced Cellular Uptake at Tumor pH. , 2015, Angewandte Chemie.

[42]  E. Bermes,et al.  Changes in plasma proteins during pregnancy. , 1978, Annals of clinical and laboratory science.

[43]  P. Das,et al.  Probing protein adsorption on a nanoparticle surface using second harmonic light scattering. , 2016, Physical chemistry chemical physics : PCCP.

[44]  Chor Yong Tay,et al.  Understanding and exploiting nanoparticles' intimacy with the blood vessel and blood. , 2015, Chemical Society reviews.

[45]  S. Bhatia,et al.  Nanotechnology: emerging tools for biology and medicine , 2013, Genes & development.

[46]  Kristofer J. Thurecht,et al.  Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date , 2016, Pharmaceutical Research.

[47]  C. Fan,et al.  Protein corona-mediated mitigation of cytotoxicity of graphene oxide. , 2011, ACS nano.

[48]  M. Tóth,et al.  In vitro and in vivo complement activation and related anaphylactic effects associated with polyethylenimine and polyethylenimine-graft-poly(ethylene glycol) block copolymers. , 2011, Biomaterials.

[49]  F. Chiti,et al.  SERS Detection of Amyloid Oligomers on Metallorganic-Decorated Plasmonic Beads. , 2015, ACS applied materials & interfaces.

[50]  David W. Russell,et al.  SDS-Polyacrylamide Gel Electrophoresis of Proteins. , 2006, CSH protocols.

[51]  Jong-Min Lim,et al.  Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics , 2017, Nature Communications.

[52]  Hermann B. Frieboes,et al.  Distribution of PLGA-modified nanoparticles in 3D cell culture models of hypo-vascularized tumor tissue , 2017, Journal of Nanobiotechnology.

[53]  Satya Prakash Yadav,et al.  Multiple Binding Sites in Fibrinogen for Integrin αMβ2 (Mac-1)* , 2004, Journal of Biological Chemistry.

[54]  R. Amal,et al.  Nanoparticle-protein corona complexes govern the biological fates and functions of nanoparticles. , 2014, Journal of materials chemistry. B.

[55]  A. Pries,et al.  Blood flow resistance during hemodilution: effect of plasma composition. , 1998, Cardiovascular research.

[56]  A. Saboury,et al.  Biomolecular Corona Dictates Aβ Fibrillation Process. , 2018, ACS chemical neuroscience.

[57]  Arezou A Ghazani,et al.  Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. , 2006, Nano letters.

[58]  A. Eisen,et al.  Amyotrophic lateral sclerosis: Amino acid levels in plasma and cerebrospinal fluid , 1990, Annals of neurology.

[59]  S. Laurent,et al.  Superparamagnetic iron oxide nanoparticles alter expression of obesity and T2D-associated risk genes in human adipocytes , 2013, Scientific Reports.

[60]  M. Rösslein,et al.  Personalized medicine: the enabling role of nanotechnology. , 2016, Nanomedicine.

[61]  S. Stolte,et al.  The nanoparticle biomolecule corona: lessons learned - challenge accepted? , 2015, Chemical Society reviews.

[62]  F Atyabi,et al.  Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents , 2011, International journal of nanomedicine.

[63]  Morteza Mahmoudi,et al.  Cell "vision": complementary factor of protein corona in nanotoxicology. , 2012, Nanoscale.

[64]  Xinlong Wang,et al.  Influence of cell size on cellular uptake of gold nanoparticles. , 2016, Biomaterials science.

[65]  Andrew J Chetwynd,et al.  Current Application of Capillary Electrophoresis in Nanomaterial Characterisation and Its Potential to Characterise the Protein and Small Molecule Corona , 2018, Nanomaterials.

[66]  B. Brenner Haemostatic changes in pregnancy. , 2004, Thrombosis research.

[67]  Peter Wipf,et al.  Nanoparticles in cellular drug delivery. , 2009, Bioorganic & medicinal chemistry.

[68]  G. Caracciolo,et al.  Lipid composition: a “key factor” for the rational manipulation of the liposome–protein corona by liposome design , 2015 .

[69]  Stefan Tenzer,et al.  Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. , 2013, Nature nanotechnology.

[70]  E. Brun,et al.  Could nanoparticle corona characterization help for biological consequence prediction? , 2014, Cancer Nanotechnology.

[71]  Zhipeng Lin,et al.  Probing the mechanism of plasma protein adsorption on Au and Ag nanoparticles with FT-IR spectroscopy. , 2015, Nanoscale.

[72]  M. Mahmoudi Protein corona: The golden gate to clinical applications of nanoparticles. , 2016, The international journal of biochemistry & cell biology.

[73]  Luca Costantino,et al.  Interaction of nanoparticles with immunocompetent cells: nanosafety considerations. , 2012, Nanomedicine.

[74]  Jianjun Cheng,et al.  Protein corona significantly reduces active targeting yield. , 2013, Chemical communications.

[75]  Jayanth Panyam,et al.  The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. , 2010, Biomaterials.

[76]  B. Jonsson,et al.  Adsorption of Human Carbonic Anhydrase II Variants to Silica Nanoparticles Occur Stepwise: Binding Is Followed by Successive Conformational Changes to a Molten-Globule-like State , 2000 .

[77]  V. Puntes,et al.  Physicochemical characteristics of protein-NP bioconjugates: the role of particle curvature and solution conditions on human serum albumin conformation and fibrillogenesis inhibition. , 2012, Langmuir : the ACS journal of surfaces and colloids.

[78]  T. Xia,et al.  Understanding biophysicochemical interactions at the nano-bio interface. , 2009, Nature materials.

[79]  Hirenkumar K. Makadia,et al.  Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. , 2011, Polymers.

[80]  Qun Huo,et al.  Gold nanoparticle-enabled blood test for early stage cancer detection and risk assessment. , 2015, ACS applied materials & interfaces.

[81]  G. Caracciolo,et al.  The protein corona of circulating PEGylated liposomes. , 2016, Biochimica et biophysica acta.

[82]  B. Morris,et al.  The protein and lipid composition of the plasma of different animal species determined by zone electrophoresis and chemical analysis. , 1955, Quarterly journal of experimental physiology and cognate medical sciences.

[83]  Joachim O Rädler,et al.  Understanding the Kinetics of Protein–Nanoparticle Corona Formation , 2016, ACS nano.

[84]  W. Parak,et al.  Techniques for the experimental investigation of the protein corona. , 2017, Current opinion in biotechnology.

[85]  P. Lansbury,et al.  Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. , 2000, Biochemistry.

[86]  G. Caracciolo,et al.  Analytical Methods for Characterizing the Nanoparticle–Protein Corona , 2014, Chromatographia.

[87]  Giulio Caracciolo,et al.  Surface chemistry and serum type both determine the nanoparticle-protein corona. , 2015, Journal of proteomics.

[88]  R. Müller,et al.  'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. , 2000, Colloids and surfaces. B, Biointerfaces.

[89]  Sílvia A. Ferreira,et al.  Biocompatibility of mannan nanogel--safe interaction with plasma proteins. , 2012, Biochimica et biophysica acta.

[90]  S Gordon,et al.  Macrophage receptors and immune recognition. , 2005, Annual review of immunology.

[91]  M. Mahmoudi,et al.  Personalized disease-specific protein corona influences the therapeutic impact of graphene oxide. , 2015, Nanoscale.

[92]  R. Sabaté,et al.  Evidence of Protein Adsorption in Pegylated Liposomes: Influence of Liposomal Decoration , 2017, Nanomaterials.

[93]  Ran Chen UNDERSTANDING NANOPARTICLE-CELL INTERACTION , 2012 .

[94]  Bengt Fadeel,et al.  Safety assessment of nanomaterials: implications for nanomedicine. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[95]  Massimiliano Papi,et al.  Principal component analysis of personalized biomolecular corona data for early disease detection , 2018, Nano Today.

[96]  Kenneth A. Dawson,et al.  Protein–Nanoparticle Interactions , 2008, Nano-Enabled Medical Applications.

[97]  R. Dinarvand,et al.  Osmolarity: A hidden factor in Nanotoxicology , 2016, DARU Journal of Pharmaceutical Sciences.

[98]  Q. Huo,et al.  Developing a nanoparticle test for prostate cancer scoring , 2012, Journal of Translational Medicine.

[99]  Sara Linse,et al.  Inhibition of amyloid beta protein fibrillation by polymeric nanoparticles. , 2008, Journal of the American Chemical Society.

[100]  S. Pun,et al.  3-D tissue culture systems for the evaluation and optimization of nanoparticle-based drug carriers. , 2008, Bioconjugate chemistry.

[101]  James Chen Yong Kah,et al.  Optimizing the properties of the protein corona surrounding nanoparticles for tuning payload release. , 2013, ACS nano.

[102]  Marina A Dobrovolskaia,et al.  Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[103]  R. Haag,et al.  Protein Corona Formation on Colloidal Polymeric Nanoparticles and Polymeric Nanogels: Impact on Cellular Uptake, Toxicity, Immunogenicity, and Drug Release Properties. , 2017, Biomacromolecules.

[104]  M. Ferrari,et al.  The nano-plasma interface: Implications of the protein corona. , 2014, Colloids and surfaces. B, Biointerfaces.

[105]  Morteza Mahmoudi,et al.  Nanotoxicology: advances and pitfalls in research methodology. , 2015, Nanomedicine.

[106]  D. Marsh,et al.  Interaction of human serum albumin with membranes containing polymer-grafted lipids: spin-label ESR studies in the mushroom and brush regimes. , 2002, Biochimica et biophysica acta.

[107]  Chawnshang Chang,et al.  Suppression Versus Induction of Androgen Receptor Functions by the Phosphatidylinositol 3-Kinase/Akt Pathway in Prostate Cancer LNCaP Cells with Different Passage Numbers* , 2003, Journal of Biological Chemistry.

[108]  J. Reynolds,et al.  Nanomedicine applied to translational oncology: A future perspective on cancer treatment. , 2016, Nanomedicine : nanotechnology, biology, and medicine.

[109]  H. Fenniri,et al.  Nanotechnology-based drug delivery systems , 2007, Journal of occupational medicine and toxicology.

[110]  K. Dawson,et al.  The Protein Corona Mediates the Impact of Nanomaterials and Slows Amyloid Beta Fibrillation , 2013, Chembiochem : a European journal of chemical biology.

[111]  Kenneth A. Dawson,et al.  Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. , 2011, Nature nanotechnology.

[112]  Mélanie Auffan,et al.  Protein corona formation for nanomaterials and proteins of a similar size: hard or soft corona? , 2013, Nanoscale.

[113]  Aniket Magarkar,et al.  Rational design of liposomal drug delivery systems, a review: Combined experimental and computational studies of lipid membranes, liposomes and their PEGylation. , 2016, Biochimica et biophysica acta.

[114]  Y. Zu,et al.  Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy , 2014, Molecular therapy. Nucleic acids.

[115]  M. Grunze,et al.  MOLECULAR CONFORMATION AND SOLVATION OF OLIGO(ETHYLENE GLYCOL)-TERMINATED SELF-ASSEMBLED MONOLAYERS AND THEIR RESISTANCE TO PROTEIN ADSORPTION , 1997 .

[116]  N. Durán,et al.  Influence of protein corona on the transport of molecules into cells by mesoporous silica nanoparticles. , 2013, ACS applied materials & interfaces.

[117]  K. Landfester,et al.  Exploiting the biomolecular corona: pre-coating of nanoparticles enables controlled cellular interactions. , 2018, Nanoscale.

[118]  D. Rubinsztein,et al.  Protein misfolding disorders and macroautophagy , 2011, Current opinion in cell biology.

[119]  Min Wu,et al.  Aptamers: Active Targeting Ligands for Cancer Diagnosis and Therapy , 2015, Theranostics.

[120]  M. Wiemann,et al.  Interlaboratory comparison of size measurements on nanoparticles using nanoparticle tracking analysis (NTA) , 2013, Journal of Nanoparticle Research.

[121]  Wolfgang J Parak,et al.  A Decade of the Protein Corona. , 2017, ACS nano.

[122]  V. Torchilin,et al.  Which polymers can make nanoparticulate drug carriers long-circulating? , 1995 .

[123]  Y. M. Thasneem,et al.  Glucosylated polymeric nanoparticles: a sweetened approach against blood compatibility paradox. , 2013, Colloids and surfaces. B, Biointerfaces.

[124]  Parag Aggarwal,et al.  Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. , 2009, Advanced drug delivery reviews.

[125]  M. Uesaka,et al.  Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. , 2011, Nature nanotechnology.

[126]  Alexander M. Seifalian,et al.  Toxicology and clinical potential of nanoparticles , 2011, Nano today.

[127]  Raimo Hartmann,et al.  Temperature: the "ignored" factor at the NanoBio interface. , 2013, ACS nano.

[128]  M. Mahmoudi,et al.  Bypassing Protein Corona Issue on Active Targeting: Zwitterionic Coatings Dictate Specific Interactions of Targeting Moieties and Cell Receptors. , 2016, ACS applied materials & interfaces.

[129]  Warren C W Chan,et al.  Nanoparticle-blood interactions: the implications on solid tumour targeting. , 2015, Chemical communications.

[130]  C. Duvall,et al.  Zwitterionic Nanocarrier Surface Chemistry Improves siRNA Tumor Delivery and Silencing Activity Relative to Polyethylene Glycol. , 2017, ACS nano.

[131]  Iseult Lynch,et al.  The evolution of the protein corona around nanoparticles: a test study. , 2011, ACS nano.

[132]  Si-Shen Feng,et al.  Folate-decorated poly(lactide-co-glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery. , 2007, Biomaterials.

[133]  Stefan Tenzer,et al.  Quantitative profiling of the protein coronas that form around nanoparticles , 2014, Nature Protocols.

[134]  Tomasz Jetka,et al.  Signaling pathway activation drift during aging: Hutchinson-Gilford Progeria Syndrome fibroblasts are comparable to normal middle-age and old-age cells , 2015, Aging.

[135]  M. Mahmoudi,et al.  Impact of protein pre-coating on the protein corona composition and nanoparticle cellular uptake. , 2016, Biomaterials.

[136]  Michael Maskos,et al.  Protein corona – from molecular adsorption to physiological complexity , 2015, Beilstein journal of nanotechnology.

[137]  Valerie M. Weaver,et al.  A tense situation: forcing tumour progression , 2009, Nature Reviews Cancer.

[138]  Wolfgang J. Parak,et al.  Back to Basics: Exploiting the Innate Physico‐chemical Characteristics of Nanomaterials for Biomedical Applications , 2014 .

[139]  C. Xiang,et al.  Effects of donors' age and passage number on the biological characteristics of menstrual blood-derived stem cells. , 2015, International journal of clinical and experimental pathology.

[140]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[141]  J. Richie,et al.  Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[142]  Morteza Mahmoudi,et al.  Emerging understanding of the protein corona at the nano-bio interfaces , 2016 .

[143]  Joo-Youp Lee,et al.  Modulation of in vitro phagocytic uptake and immunogenicity potential of modified Herceptin®-conjugated PLGA-PEG nanoparticles for drug delivery. , 2018, Colloids and surfaces. B, Biointerfaces.

[144]  B. Liedberg,et al.  Component-Specific Analysis of Plasma Protein Corona Formation on Gold Nanoparticles Using Multiplexed Surface Plasmon Resonance. , 2016, Small.

[145]  Ventola Cl,et al.  Progress in Nanomedicine: Approved and Investigational Nanodrugs. , 2017 .

[146]  Bessi Qorri,et al.  Recent advances in “smart” delivery systems for extended drug release in cancer therapy , 2018, International journal of nanomedicine.

[147]  Sara Linse,et al.  Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles , 2007, Proceedings of the National Academy of Sciences.

[148]  R. Pawar,et al.  In-vitro in-vivo correlation (IVIVC) in nanomedicine: Is protein corona the missing link? , 2017, Biotechnology advances.

[149]  Wolfgang J Parak,et al.  Effects of surface functionalization on the adsorption of human serum albumin onto nanoparticles – a fluorescence correlation spectroscopy study , 2014, Beilstein journal of nanotechnology.

[150]  Philip J. Smith,et al.  Cellular entry of nanoparticles via serum sensitive clathrin-mediated endocytosis, and plasma membrane permeabilization , 2012, International journal of nanomedicine.

[151]  C. Dobson,et al.  Protein misfolding, functional amyloid, and human disease. , 2006, Annual review of biochemistry.

[152]  Kenneth A. Dawson,et al.  Effects of the presence or absence of a protein corona on silica nanoparticle uptake and impact on cells. , 2012, ACS nano.

[153]  Aristidis Tsatsakis,et al.  Protein bio-corona: critical issue in immune nanotoxicology , 2016, Archives of Toxicology.

[154]  C. K. Nandi,et al.  Controlling the Fate of Protein Corona by Tuning Surface Properties of Nanoparticles , 2013 .

[155]  Thomas J Webster,et al.  Effect of the protein corona on nanoparticles for modulating cytotoxicity and immunotoxicity , 2014, International journal of nanomedicine.

[156]  Balu Ranganathan,et al.  Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. , 2008, Biomaterials.

[157]  Morteza Mahmoudi,et al.  Debugging Nano-Bio Interfaces: Systematic Strategies to Accelerate Clinical Translation of Nanotechnologies. , 2018, Trends in biotechnology.

[158]  Juan Li,et al.  A review of the ligands and related targeting strategies for active targeting of paclitaxel to tumours , 2016, Journal of drug targeting.

[159]  Ruedi Aebersold,et al.  Quantitative variability of 342 plasma proteins in a human twin population , 2015 .

[160]  M. Mahmoudi,et al.  Plasma concentration gradient influences the protein corona decoration on nanoparticles , 2013 .

[161]  Svetlana Gelperina,et al.  Adsorption of plasma proteins on uncoated PLGA nanoparticles. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[162]  S. Mandava,et al.  In Vitro/In Vivo Toxicity Evaluation and Quantification of Iron Oxide Nanoparticles , 2015, International journal of molecular sciences.

[163]  M. Mahmoudi,et al.  Protein-nanoparticle interactions: opportunities and challenges. , 2011, Chemical reviews.

[164]  D. Jaillard,et al.  Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments. , 2005, Bioconjugate chemistry.

[165]  Christoffer Åberg,et al.  Mapping protein binding sites on the biomolecular corona of nanoparticles. , 2015, Nature nanotechnology.

[166]  Wolfgang J Parak,et al.  A quantitative fluorescence study of protein monolayer formation on colloidal nanoparticles. , 2009, Nature nanotechnology.

[167]  W. Jiskoot,et al.  Measurement of the average mass of proteins adsorbed to a nanoparticle by using a suspended microchannel resonator. , 2015, Journal of pharmaceutical sciences.

[168]  Urs O. Häfeli,et al.  Crucial Ignored Parameters on Nanotoxicology: The Importance of Toxicity Assay Modifications and “Cell Vision” , 2012, PloS one.

[169]  M. Mahmoudi,et al.  Protein fibrillation and nanoparticle interactions: opportunities and challenges. , 2013, Nanoscale.

[170]  K. Landfester,et al.  Protein corona change the drug release profile of nanocarriers: the "overlooked" factor at the nanobio interface. , 2014, Colloids and surfaces. B, Biointerfaces.

[171]  Francesco Salvatore,et al.  The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery. , 2016, Nanomedicine.

[172]  Alaaldin M. Alkilany,et al.  Protein corona: Opportunities and challenges. , 2016, The international journal of biochemistry & cell biology.

[173]  Albert Duschl,et al.  Time evolution of the nanoparticle protein corona. , 2010, ACS nano.

[174]  G. Caracciolo,et al.  Stealth effect of biomolecular corona on nanoparticle uptake by immune cells. , 2015, Langmuir : the ACS journal of surfaces and colloids.

[175]  Giulio Caracciolo,et al.  Size and charge of nanoparticles following incubation with human plasma of healthy and pancreatic cancer patients. , 2014, Colloids and surfaces. B, Biointerfaces.

[176]  K. Landfester,et al.  Visualization of the protein corona: towards a biomolecular understanding of nanoparticle-cell-interactions. , 2017, Nanoscale.

[177]  M. Platt,et al.  Characterisation of the protein corona using tunable resistive pulse sensing: determining the change and distribution of a particle’s surface charge , 2016, Analytical and Bioanalytical Chemistry.

[178]  Wolfgang J. Parak,et al.  Protein corona formation around nanoparticles – from the past to the future , 2014 .

[179]  M. Coelho,et al.  Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer's disease treatment. , 2016, Colloids and surfaces. B, Biointerfaces.

[180]  Artur Bednarkiewicz,et al.  Upconverting nanoparticles: assessing the toxicity. , 2015, Chemical Society reviews.

[181]  Christine Jérôme,et al.  Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[182]  Kenneth A. Dawson,et al.  Transferrin Coated Nanoparticles: Study of the Bionano Interface in Human Plasma , 2012, PloS one.

[183]  M. Bawendi,et al.  Renal clearance of quantum dots , 2007, Nature Biotechnology.

[184]  Philip M. Kelly,et al.  Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. , 2013, Nature nanotechnology.

[185]  M. Mahmoudi,et al.  Graphene oxide strongly inhibits amyloid beta fibrillation. , 2012, Nanoscale.

[186]  Mauro Ferrari,et al.  Shrinkage of pegylated and non-pegylated liposomes in serum. , 2014, Colloids and surfaces. B, Biointerfaces.

[187]  Samir Mitragotri,et al.  Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. , 2010, Current pharmaceutical design.

[188]  Raimo Hartmann,et al.  Surface Functionalization of Nanoparticles with Polyethylene Glycol: Effects on Protein Adsorption and Cellular Uptake. , 2015, ACS nano.

[189]  G. Caracciolo,et al.  The biomolecular corona of nanoparticles in circulating biological media. , 2015, Nanoscale.

[190]  M. Mahmoudi,et al.  Protein corona composition of gold nanoparticles/nanorods affects amyloid beta fibrillation process. , 2015, Nanoscale.

[191]  Sara Linse,et al.  Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. , 2007, Angewandte Chemie.

[192]  B. Ruozi,et al.  Protein corona and nanoparticles: how can we investigate on? , 2017, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[193]  Ruhong Zhou,et al.  Towards understanding of nanoparticle–protein corona , 2015, Archives of Toxicology.

[194]  Vera Ignjatovic,et al.  Age-Related Differences in Plasma Proteins: How Plasma Proteins Change from Neonates to Adults , 2011, PloS one.

[195]  Ravi S Kane,et al.  Antifouling Coatings: Recent Developments in the Design of Surfaces That Prevent Fouling by Proteins, Bacteria, and Marine Organisms , 2011, Advanced materials.

[196]  Vicki Stone,et al.  Efficacy of Simple Short-Term in Vitro Assays for Predicting the Potential of Metal Oxide Nanoparticles to Cause Pulmonary Inflammation , 2008, Environmental health perspectives.

[197]  Warren C W Chan,et al.  Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. , 2012, Chemical Society reviews.

[198]  Si-Shen Feng,et al.  Nanoparticles of biodegradable polymers for new-concept chemotherapy , 2004, Expert review of medical devices.

[199]  James E Bear,et al.  PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. , 2012, Nano letters.

[200]  M. Mahmoudi,et al.  Cell shape affects nanoparticle uptake and toxicity: An overlooked factor at the nanobio interfaces. , 2018, Journal of colloid and interface science.